FDA Drug Approval Summary: Azacitidine (5-azacytidine, Vidaza^TM) for Injectable Suspension

FDA Drug Approval Summary: Azacitidine (5-azacytidine, Vidaza™) for Injectable Suspension Edvardas Kaminskas, Ann T. Farrell, Yong-Cheng Wang, Rajeshwari Sridhara, Richard Pazdur Oncologist 2005; 10: 176-182 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine and FDA information, and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Describe the indication and rationale for using azacitidine. Discuss the relative effectiveness of azacitidine. Identify the limitations of treatment with azacitidine. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Mar. 25, 2005 Most Recent Review: Mar. 25, 2005* Most Recent Update: Mar. 25, 2005 Date Credit Expires: Apr. 12, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.